User login
The Omnibus Spending Bill approved by the House and Senate on Dec. 18, 2015, and later signed by President Obama includes several provisions that NORD and its advocacy partners supported, including a 7% funding increase for NIH, a 5% increase for FDA, and extension of the Rare Pediatric Disease Priority Review Voucher Program, which had been set to expire in March 2016.
The Omnibus Spending Bill approved by the House and Senate on Dec. 18, 2015, and later signed by President Obama includes several provisions that NORD and its advocacy partners supported, including a 7% funding increase for NIH, a 5% increase for FDA, and extension of the Rare Pediatric Disease Priority Review Voucher Program, which had been set to expire in March 2016.
The Omnibus Spending Bill approved by the House and Senate on Dec. 18, 2015, and later signed by President Obama includes several provisions that NORD and its advocacy partners supported, including a 7% funding increase for NIH, a 5% increase for FDA, and extension of the Rare Pediatric Disease Priority Review Voucher Program, which had been set to expire in March 2016.
